|
|
|
|
|
|
|
|
|
|
(case report/review) Conclusions Endometrioid ovarian carcinoma may benefit from aromatase inhibitors, especially when the tumour burden is low after primary chemotherapy or when the inhibitor is used as maintenance therapy between chemotherapies.
Tuesday, November 30, 2010
Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review (abstract) Dr Yi Pan (author)
(case report/review) Conclusions Endometrioid ovarian carcinoma may benefit from aromatase inhibitors, especially when the tumour burden is low after primary chemotherapy or when the inhibitor is used as maintenance therapy between chemotherapies.
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.